Evaxion Biotech A/S (EVAX) Expected to Announce Earnings on Tuesday

Evaxion Biotech A/S (NASDAQ:EVAX) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 27th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $0.06 million for the quarter.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Tuesday, April 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.19. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $1.66 million. On average, analysts expect Evaxion Biotech A/S to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Evaxion Biotech A/S Price Performance

EVAX opened at $1.88 on Monday. Evaxion Biotech A/S has a 12-month low of $1.20 and a 12-month high of $20.81. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The business’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $3.50. The company has a market capitalization of $2.64 million, a price-to-earnings ratio of -1.30 and a beta of -0.24.

Wall Street Analyst Weigh In

EVAX has been the subject of a number of analyst reports. Lake Street Capital decreased their price objective on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research note on Wednesday, April 2nd.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.